Rangkuman
x KonselingpadapasienHIVbertujuanuntukmemberiinformasistatusHIVpasiendanbila terinfeksimemperolehpelayananmedisdanpsikososialyangsesuaidanmendorong pasienuntukmelakukanperubahanperilakuuntukmenghindariinfeksimaupun mencegahpenularaninfeksikeoranglain
x KonselingdantesHIVyangkinidirekomendasikanadalahproviderͲinitiatedtestingand
counseling(PITC),dimanatenagakesehatanberperanaktifdalammenawarkankonseling dantesHIVkepadaklien
x PITCdianjurkanuntukdilakukanpadaseluruhlevellayanankesehatan
x WHOmerekomendasikankonselingdantesHIVpadakomunitaskunci,yaituLSL,penasun, pasanganpenasun,transgender,WPS,danWBP.Konselingdantesdirekomendasikan diulangtiap6Ͳ12bulan
x SkrininghepatitisCjugaperludilakukanpadapopulasikunci
DAFTARPUSTAKA
1. TaylorLE,SwanT,MayerKH.HIVcoinfectionwithhepatitisCvirus:evolvingepidemiology andtreatmentparadigms.ClinInfectDis.2012;55:33Ͳ42.
2. CowieB,DoreG,SasadeuszJ,editors.CoͲinfection:HIV&ViralHepatitis,AGuideforClinical Management.4thed.Darlinghurst:AustralasianSocietyforHIVMedicine(ASHM);2010. 3. AndreoniM,GiacomettiA,MaidaI,MeravigliaP,RipamontiD,SarmatiL.HIVͲHCVcoͲ
infection:epidemiology,pathogenesisandtherapeuticimplications.EurRevMedPharmacol Sci.2012;16(11):1473Ͳ83.
4. SulkowskiMS,MooreRD,MehtaSH,ChaissonRE,ThomasDL.HepatitisCandprogressionof HIVdisease.JAMA.2002;288(2):199Ͳ206.
5. GreubG,LedergerberB,BattegayM,GrobP,PerrinL,FurrerH,etal.Clinicalprogression, survival,andimmunerecoveryduringantiretroviraltherapyinpatientswithHIVͲ1and hepatitisCviruscoinfection:theSwissHIVCohortStudy.Lancet.2000;356(9244):1800Ͳ5. 6. DengLP,GuiXE,ZhangYX,GaoSC,YangRR.Impactofhumanimmunodeficiencyvirus
infectiononthecourseofhepatitisCvirusinfection:ametaͲanalysis.WorldJGastroenterol. 2009;15(8):996Ͳ1003.
7. NationalCenterforHIVAIDSVH,STD,andTBPrevention.HIVandViralHepatitis.Centersfor DiseaseControlandPrevention;2013.
8. PonamgiSP,RahamathullaS,KumarYN,ChandraM,LakshmiN,HabibullahCM,etal. PrevalenceofhepatitisCvirus(HCV)coinfectioninHIVinfectedindividualsinsouthIndiaand characterizationofHCVgenotypes.IndianJMedMicrobiol.2009;27(1):12Ͳ6.
9. AlterMJ,HadlerSC,JudsonFN,MaresA,AlexanderWJ,HuPY,etal.Riskfactorsforacute nonͲA,nonͲBhepatitisintheUnitedStatesandassociationwithhepatitisCvirusinfection. JAMA.1990;264(17):2231Ͳ5.
10. Gani RA, Budihusodo U, Waspodo A, Lesmana LA, Hasan I, Akbar N, et al. Seroepidemiology and risk factors of HepaƟƟƐB and C virus infecƟons among drug users in Jakarta, Indonesia. Med J Indones. 2002;11(1).
11. Tohme RA, Holmberg SD. Is sexual contact a major mode of hepaƟƟs C virus transmission? Hepatology. 2010;52(4):1497 505.
12. Zylberberg H, Thiers V, Lagorce D, Squadrito G, Leone F, Berthelot P, et al. Epidemiological and virological analysis of couples infected with heƉĂƟƟs C virus. Gut. 1999;45(1):112 6. 13. Tahan V, Karaca C, Yildirim B, Bozbas A, Ozaras R, Demir K. Sexual transmission of HCV
between spouses. Am J Gastroenterol. 2005;100:821 4.
14. KurniawaƟSA. Faktor faktor yang berhubungan dengan kejadian hepaƟƟs C pada pasangan seksual pasien koinfeksihuman immunodeĮciency virusdanhepaƟƟs C virus. Tesis Program Pendidikan Dokter Spesialis 1: Fakultas Kedokteran Universitas Indonesia; 2008.
15. van de Laar T, Pybus O, Bruisten S, Brown D, Nelson M, Bhagani S, et al. Evidence of a large, internaƟŽŶĂů network of HCV transmission in HIV posiƟve men who have sex with men. Gastroenterology. 2009;136(5):1609 17.
16. ZaneƫAR, Tanzi E, Paccagnini S, Principi N, Pizzocolo G, Caccamo ML, et al. Mother to infant transmission of hepaƟƟs C virus. Lombardy Study Group on VerƟcal HCV Transmission. Lancet. 1995;345(8945):289 91.
17. Minosse C, Calcaterra S, Abbate I, Selleri M, ZanirĂƫ MS, Capobianchi MR. Possible compartmĞŶƚĂůŝnjĂƟŽŶ ofŚĞƉĂƟƟs C viral replicaƟŽn in the genital tract of HIV 1 coinfected women. J Infect Dis. 2006;194(11):1529 36.
18. Briat A, Dulioust E, Galimand J, Fontaine H, Chaix ML, Letur Konirsch H, et al.,ĞƉĂƟƟs C virus in the semen of men coinfected with HIV 1: prevalence and origin. Aids. 2005;19(16):1827 35. 19. MaƩhews Greer JM, Caldito GC, Adley SD, Willis R, Mire AC, Jamison RM, et al. Comparison of ŚĞƉĂƟƟs C viral loads in paƟents with or without human immunodeĮciency virus. Clin Diagn Lab Immunol. 2001;8(4):690 4.
20. Bonacini M, Govindarajan S, BlĂƩ LM, Schmid P, Conrad A, Lindsay KL. PaƟents co infected with human immƵŶŽĚĞĮĐiency virus and hepaƟƟs C virus demonstrate higher levels of ŚĞƉĂƟĐHCV RNA. J Viral Hepat. 1999;6(3):203 8.
21. Dore GJ, Torriani FJ, Rodriguez Torres M, Brau N, Sulkowski M, Lamoglia RS, et al. Baseline factors prognosƟc of sustained virological response in paƟents with HIVŚĞƉĂƟƟƐC virus co infecƟon. Aids. 2007;21(12):1555 9.
22. Cooper CL, Cameron DW. Eīect of alcohol use and highly ĂĐƟǀĞ anƟretroviral therapy on plasma levels of hepaƟƟƐ C virus (HCV) in paƟents coinfected with HIV and HCV. Clin Infect Dis. 2005;41:105 9.
23. Danta M, Semmo N, Fabris P, Brown D, Pybus OG, Sabin CA, et al. Impact of HIV on host virus interacƟŽŶƐduring earlyŚĞƉĂƟƟs C virus infecƟon. J Infect Dis. 2008;197(11):1558 66. 24. Ghany MG, Strader DB, Thomas DL, Seeī LB, American AssociĂƟŽŶfor the Study of Liver D.
25. SotoB,SanchezͲQuijanoA,RodrigoL,delOlmoJA,GarciaͲBengoecheaM,HernandezͲQuero J,etal.Humanimmunodeficiencyvirusinfectionmodifiesthenaturalhistoryofchronic parenterallyͲacquiredhepatitisCwithanunusuallyrapidprogressiontocirrhosis.JHepatol. 1997;26(1):1Ͳ5.
26. BrauN,FoxRK,XiaoP,MarksK,NaqviZ,TaylorLE,etal.Presentationandoutcomeof hepatocellularcarcinomainHIVͲinfectedpatients:aU.S.ͲCanadianmulticenterstudy.J Hepatol.2007;47(4):527Ͳ37.
27. PuotiM,BrunoR,SorianoV,DonatoF,GaetaGB,QuinzanGP,etal.Hepatocellularcarcinoma inHIVͲinfectedpatients:epidemiologicalfeatures,clinicalpresentationandoutcome.Aids. 2004;18(17):2285Ͳ93.
28. DaarES,LynnH,DonfieldS,GompertsE,HilgartnerMW,HootsWK,etal.Relationbetween HIVͲ1andhepatitisCviralloadinpatientswithhemophilia.JAcquirImmuneDeficSyndr. 2001;26(5):466Ͳ72.
29. Ghany MG, Leissinger C, Lagier R, SanchezͲPescador R, Lok AS. Effect of human immunodeficiencyvirusinfectiononhepatitisCvirusinfectioninhemophiliacs.DigDisSci. 1996;41(6):1265Ͳ72.
30. PetersL,MocroftA,SorianoV,RockstrohJK,LossoM,ValerioL.HepatitisCviruscoͲinfection doesnotinfluencetheCD4cellrecoveryinHIVͲ1Ͳinfectedpatientswithmaximumvirologic suppression.JAcquiImmuneDeficSyndr.2009;50(5):457Ͳ63.
31. CollinsS,SwanT.GuidetoHepatitisCforPeopleLivingwithHIV.USA:HIViͲBaseandTAG; 2013.
32. WorldHealthOrganization.ManagementofHepatitisCandHIVCoinfectionͲClinicalProtocol fortheWHOEuropeanRegion:WHOEurope;2009.
33. GürtlerL.DifficultiesandstrategiesofHIVdiagnosis.Lancet.1996;348(9021):176Ͳ9.
34. SteklerJD,SwensonPD,CoombsRW,DragavonJ,ThomasKK,BrennanCA,etal.HIVtestingin a highͲincidence population:is antibody testing alonegood enough? Clin InfectDis. 2009;49(3):444Ͳ53.
35. JacksonJB,ParsonsJS,NicholsLS,KnobleN,KennedyS,PiwowarEM.Detectionofhuman immunodeficiencyvirustype1(HIVͲ1)antibodybywesternblottingandHIVͲ1DNAbyPCRin patientswithAIDS.JClinMicrobiol.1997;35(5):1118Ͳ21.
36. JanssenRS,SattenGA,StramerSL,RawalBD,O'BrienTR,WeiblenBJ,etal.Newtesting strategytodetectearlyHIVͲ1infectionforuseinincidenceestimatesandforclinicaland preventionpurposes.JAMA.1998;280(1):42Ͳ8.
37. LewJ,ReichelderferP,FowlerM,BremerJ,CarrolR,CassolS,etal.Determinationsoflevels ofhumanimmunodeficiencyvirustype1RNAinplasma:reassessmentofparameters affectingassayoutcome.JClinMicrobiol.1998;36(6):1471Ͳ9.
38. GreenwaldJL,BursteinGR,PincusJ,BransonB.ArapidreviewofrapidHIVantibodytests. CurrInfectDisRep.2006;8(2):125Ͳ31.
39. ShresthaRK,ClarkHA,SansomSL,SongB,BuckendahlH,CalhounCB,etal.CostͲeffectiveness offindingnewHIVdiagnosesusingrapidHIVtestingincommunityͲbasedorganizations. PublicHealthRep.2008;123(Suppl3):94.
40. ReimannKA,O'GormanMR,SpritzlerJ,WilkeningCL,SabathDE,HelmK,etal.Multisite comparison ofCD4andCD8TͲlymphocytecountingbysingleͲversusmultipleͲplatform methodologies:evaluationofBeckmanCoulterflowͲcountfluorospheresandthetetraONE system.ClinDiagnLabImmunol.2000;7(3):344Ͳ51.
41. O'BrienWA,HartiganPM,MartinD,EsinhartJ,HillA,BenoitS,etal.ChangesinplasmaHIVͲ1 RNAandCD4+lymphocytecountsandtheriskofprogressiontoAIDS.NEngJMed. 1996;334(7):426Ͳ31.
42. DouekDC,BrenchleyJM,BettsMR,AmbrozakDR,HillBJ,OkamotoY,etal.HIVpreferentially infectsHIVͲspecificCD4+Tcells.Nature.2002;417(6884):95Ͳ8.
43. WorldHealthOrganization.Consolidatedguidelinesontheuseofantiretroviraldrugsfor treatingandpreventingHIVinfection:recommendationsforapublichealthapproach.Kuala Lumpur:WHO;June2013.
44. KahnJO,WalkerBD.Acutehumanimmunodeficiencyvirustype1infection.NEngJMed. 1998;339(1):33Ͳ9.
45. SorianoV,SulkowskiM,BerginC,HatzakisA,CacoubP,KatlamaC,etal.Careofpatientswith chronichepatitisCandHIVcoͲinfection:recommendationsfromtheHIVͲHCVInternational Panel.Aids.2002;16(6):813Ͳ28.
46. TorrianiFJ,RodriguezͲTorresM,RockstrohJK,LissenE,GonzalezͲGarcíaJ,LazzarinA,etal. PeginterferonAlfaͲ2aplusribavirinforchronichepatitisCvirusinfectioninHIVͲinfected patients.NEngJMed.2004;351(5):438Ͳ50.
47. KatzensteinDA,HammerSM,HughesMD,GundackerH,JacksonJB,FiscusS,etal.The relationofvirologicandimmunologicmarkerstoclinicaloutcomesafternucleosidetherapyin HIVͲinfected adults with 200 to 500 CD4 cells per cubic millimeter. NEng J Med. 1996;335(15):1091Ͳ8.
48. WittDJ,KemperM,SteadA,GinocchioCC,CaliendoAM.Relationshipofincremental specimenvolumesandenhanceddetectionofhumanimmunodeficiencyvirustype1RNA withnucleicacidamplificationtechnology.JClinMicrobiol.2000;38(1):85Ͳ9.
49. MulderJ,McKinneyN,ChristophersonC,SninskyJ,GreenfieldL,KwokS.Rapidandsimple PCRassay forquantitationofhumanimmunodeficiencyvirustype1RNAinplasma: applicationtoacuteretroviralinfection.JClinMicrobiol.1994;32(2):292Ͳ300.
50. FoulongneV,MontesB,DidelotͲRousseauMͲN,SegondyM.ComparisonoftheLCxhuman immunodeficiencyvirus(HIV)RNAquantitative,RealTimeHIV,andCOBASAmpliPrepͲCOBAS TaqMan assays for quantitation of HIV type 1 RNA in plasma. J Clin Microbiol. 2006;44(8):2963Ͳ6.
51. RevetsH,MarissensD,DeWitS,LacorP,ClumeckN,LauwersS,etal.Comparativeevaluation ofNASBAHIVͲ1RNAQT,AMPLICORͲHIVmonitor,andQUANTIPLEXHIVRNAassay,three methodsforquantificationofhumanimmunodeficiencyvirustype1RNAinplasma.JClin Microbiol.1996;34(5):1058Ͳ64.
53. BalakrishnanP,SolomonS,KumarasamyN,MayerKH.LowͲcostmonitoringofHIVinfected individualsonhighlyactiveantiretroviraltherapy(HAART)indevelopingcountries.IndianJ MedRes.2005;121(4):345Ͳ55.
54. YeeHS,ChangMF,PochaC,LimJ,RossD,MorganTR,etal.Updateonthemanagementand treatmentofhepatitisCvirusinfection:recommendationsfromtheDepartmentofVeterans AffairsHepatitisCResourceCenterProgramandtheNationalHepatitisCProgramOffice.Am JGastroenterol.2012;107(5):669Ͳ89;quiz90.
55. FranciscusA.AGuideto:HIV/HCVCoinfection.SanFrancisco:HCVadvocate;2012.
56. Jung KS, Kim SU. Clinical applications of transient elastography. Clin Mol Hepatol. 2012;18(2):163Ͳ73.
57. MasuzakiR,TateishiR,YoshidaH,SatoT,OhkiT,GotoT,etal.Assessinglivertumorstiffness bytransientelastography.HepatolInt.2007;1(3):394Ͳ7.
58. Echosens.ClinicalHandbookFibroscan.2010:1Ͳ19.Availablefrom:http://aspͲindus.secureͲ zone.net/v2/index.jsp?id=955/1196/3607&lng=en
59. MaricD,KlasnjaB,FilipovicD,BrkicS,RuzicM,BugarskiV.Minimalhepaticencephalopathy inpatientswithdecompensatedlivercirrhosis.ActaClinCroat.2011;50(3):375Ͳ80.
60. European Association For The Study Of The Liver. EASL Clinical Practice Guidelines: managementofhepatitisCvirusinfection.JHepatol.2011;55(2):245Ͳ64.
61. OmataM,KandaT,YuM,YokosukaO,LimS,JafriW,etal.APASLconsensusstatementsand managementalgorithmsforhepatitisCvirusinfection.HepatolInt.2012.
62. GadYZ,ZaherAA,MoussaNH,ElͲdesokyAE,AlͲAdarosyHA.Screeningforminimalhepatic encephalopathy in asymptomatic drivers with liver cirrhosis. Arab J Gastroenterol. 2011;12(2):58Ͳ61.
63. RamanathanS,ChengA,MittanA,EbrahimiR,KearneyBP.Absenceofclinicallyrelevant pharmacokineticinteractionbetweenribavirinandtenofovirinhealthysubjects.JClin Pharmacol.2006;46(5):559Ͳ66.
64. ScheringCorporation.RebetolUSPrescribingInformation.November2009.Availablefrom: https://www.merck.com/product/usa/pi_circulars/r/rebetol/rebetol_pi.pdf.
65. SolasC,PambrunE,WinnockM,SalmonD,PoizotͲMartinI,DominguezS,etal.Ribavirinand abacavir drug interaction in HIV–HCV coinfected patients: fact or fiction? Aids. 2012;26(17):2193Ͳ9.
66. AmorosaVK,SlimJ,MounzerK,BrunoC,HoffmanͲTerryM,DoreyͲSteinZ,etal.Theinfluence ofabacavirandotherantiretroviralagentsonvirologicresponsetohepatitisCvirustherapy amongantiretroviralͲtreatedHIVͲinfectedpatients.AntivirTher.2010;15(1):91.
67. KasserraC,HughesE,TreitelM,GuptaS,O'MaraE,editors.Clinicalpharmacologyof boceprevir:Metabolism,excretion,anddrugͲdruginteractions.Programandabstractsofthe 18thConferenceonRetrovirusesandOpportunisticInfections(CROI)Boston,MA;2011. 68. KwoPY,LawitzEJ,McConeJ,SchiffER,VierlingJM,PoundD,etal.Efficacyofboceprevir,an
NS3proteaseinhibitor,incombinationwithpeginterferonalfaͲ2bandribavirinintreatmentͲ naivepatientswithgenotype1hepatitisCinfection(SPRINTͲ1):anopenͲlabel,randomised, multicentrephase2trial.Lancet.2010;376(9742):705Ͳ16.
69. MerckSharp&DohmeLtd.VictrelisSummaryofProductCharacteristics.March2012. Available from : http:// www.ema.europa.eu/docs/en_GB/document_library/EPAR_Ͳ _Product_Information/human/002332/WC500109786.pdf.
70. HulskotteEG,FengHP,BruceRD,WebsterLR,XuanF,LinWH,etal.Pharmacokinetic interactionbetweenHCVproteaseinhibitorboceprevirandmethadoneorbuprenorphinein subjectsonstablemaintenancetherapy.JGastroenterolHepatol.2012;27:169Ͳ70.
71. VanHeeswijkR,VandevoordeA,BoogaertsG,VangeneugdenT,DePaepeE,PoloR,etal., editors.PharmacokineticinteractionsbetweenARVagentsandtheinvestigationalHCV proteaseinhibitorTVRinhealthyvolunteers.Programandabstractsofthe18thConference onRetrovirusesandOpportunisticInfections(CROI)Boston,MA;2011.
72. VanHeeswijkR,GysenV,BoogaertsG,DePaepeE,VangeneugdenT,DeBackerK,editors. The pharmacokinetic interaction between tenofovir disoproxil fumarate and the investigationalHCVproteaseinhibitortelaprevir.48thAnnualICCAC/IDSA46thAnnual Meeting,WashingtonDC;2008.
73. McHutchisonJG,EversonGT,GordonSC,JacobsonIM,SulkowskiM,KauffmanR,etal. TelaprevirwithpeginterferonandribavirinforchronicHCVgenotype1infection.NEnglJ Med.2009;360(18):1827Ͳ38.
74. JanssenͲCilagLtd.IncivoSummaryofProductCharacteristics.March2012.Availablefrom :http://www.ema.europa.eu/docs/en_GB/document_library/EPAR__Product_Information/hu man/002313/WC500115529.pdf.
75. GargV,ChandorkarG,YangY,AddaN,McNairL,AlvesK,editors.TheeffectofCYP3A inhibitorsandinducersonthepharmacokineticsoftelaprevir.6thInternationalWorkshopon ClinicalPharmacologyofHepatitisTherapy,Cambridge,MA;2011.
76. GargV,LuoX,McNairL,vanHeeswijkR,KauffmanR.TheeffectoflowͲdoseritonavironthe pharmacokinetics of the investigational HCV protease inhibitor telaprevir in healthy volunteers.Group.2011;5500:6000.
77. VanHeeswijkR,VandevoordeA,VerbovenP,BoogaertsG,DePaepeE,VanSolingenͲRisteaR, etal.ThepharmacokineticinteractionbetweenmethadoneandtheinvestigationalHCV proteaseinhibitortelaprevir.JHepatol.2011;54:S491ͲS2.
78. ScheringCorporation.PegIntronUSPrescribingInformation.January2010.Availablefrom :http://depts.washington.edu/
hepstudy/presentations/uploads/67/hcv_rx_peg_2bmaster.pdf.
79. WeinhardtLS,CareyMP,JohnsonBT,BickhamNL.EffectsofHIVcounselingandtestingon sexualriskbehavior:ametaͲanalyticreviewofpublishedresearch,1985Ͳ1997.AmJPublic Health.1999;89(9):1397Ͳ405.
80. MakhungaͲRamfoloN,ChidarikireT,FariraiT,MatjiR.ProviderͲinitiatedcounsellingand testing(PICT):Anoverview.SAJHIVMED.2011;12(2):6,8,10,1.
81. GhanyMG,StraderDB,ThomasDL,SeeffLB.Diagnosis,management,andtreatmentof hepatitisC:anupdate.Hepatology.2009;49(4):1335Ͳ74.